BLISSGVS vs CIPLA: Stock Comparison

Bliss GVS Pharma Limited vs Cipla Ltd

Live data: 2 July 2026, 4:08 PM IST • Source: NSE and company filings

Cipla Ltd is the larger company by market capitalisation. Bliss GVS Pharma Limited shows faster revenue growth, while Cipla Ltd shows a lower P/E, a higher ROE and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Bliss GVS Pharma Limited and Cipla Ltd on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, BLISSGVS is more favourable on 4 of 13 scored metrics and CIPLA on 9These counts are context-free and are not an overall rating.

Key Differences

Market Cap
CIPLA is the larger company
₹1.14 L Cr vs ₹4,782 Cr
P/E Ratio
CIPLA has a lower P/E
29.83x vs 38.27x
P/B Ratio
CIPLA has a lower P/B
3.36x vs 4.14x
EPS
CIPLA has higher earnings per share
₹48.01 vs ₹11.99
Dividend Yield
CIPLA has a higher dividend yield
0.9% vs 0.19%
Revenue Growth (TTM YoY)
BLISSGVS has faster revenue growth
29.8% vs -2.1%
EPS Growth (TTM YoY)
BLISSGVS has faster EPS growth
124.7% vs -54.6%
Qtr Sales Growth
BLISSGVS has stronger quarterly sales growth
13% vs -2.8%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricBLISSGVSCIPLA
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricBLISSGVSCIPLA
Live Price₹527.1₹1,411.5
Day Change0.68%-1.47%
Volume3.93 L12.89 L
52-Week High₹553₹1,673
52-Week Low₹118₹1,165.7
Distance from 52W High-4.68%-15.63%

Valuation

MetricBLISSGVSCIPLA
Market Cap₹4,782 Cr₹1.14 L Cr
P/E Ratio38.27x29.83x
P/B Ratio4.14x3.36x
EPS₹11.99₹48.01
Book Value₹107.21₹426.25
Dividend Yield0.19%0.9%

Growth

MetricBLISSGVSCIPLA
Revenue Growth (TTM YoY)29.8%-2.1%
EPS Growth (TTM YoY)124.7%-54.6%
Qtr Sales Growth13%-2.8%
Qtr Profit Growth108%-54.6%

Profitability & Leverage

MetricBLISSGVSCIPLA
ROE0%11.6%
ROCE11.7%15.5%
Net Margin13.93%13.96%
Operating Margin12.82%20.9%
Debt to Equity1.77x0.02x

Shareholding

As of Mar 2026 • change vs previous quarter
MetricBLISSGVSCIPLA
Promoter Holding35.36%9.17%
FII Holding10.45% 4.09 pp22.56% 1.37 pp
DII Holding5.04% 0.74 pp31.97% 1.25 pp
Public Holding49.15% 4.83 pp16.25% 0.12 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Bliss GVS Pharma Limited and Cipla Ltd.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.